Veritus Research
Bayswater, Victoria, 3153, Australia
Location status: Recruiting
NCT Number: NCT07686484
The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Early Phase 1
Bayswater, Victoria, 3153, Australia
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Main inclusion criteria
Main exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Single dose HRS-3095 /placebo given orally - Dose level 1
Time frame: Day 8
Number of participants with Adverse events and Serious adverse events
Time frame: Day 4
Maximum observed plasma concentration (Cmax)
Time frame: Day 4
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀0-inf)
Time frame: Day 4
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 4
Terminal elimination half-life (t1/2)
Time frame: Day 8
Target occupancy assessment
Contact information is provided by the study sponsor or research team.
Eimy Minowa
CONTACT
Kathy You
CONTACT
Atridia Pty Ltd.
Industry
A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07642557
Chronic Disease, Chronic Spontaneous Urticaria
Düren, Germany
View Trial DetailsNCT07402213
Chronic Disease, Chronic Spontaneous Urticaria
Beijing, China
View Trial DetailsNCT07717905
Chronic Disease, Chronic Spontaneous Urticaria
Wuhu, Anhui, China
View Trial DetailsNCT07219615
Chronic Disease, Chronic Spontaneous Urticaria
Phoenix, Arizona, United States
View Trial Details